The trial is scheduled to begin in 2015.
No, the MRF is not recruiting patients. As more Information about this trial becomes available, details will be posted on the NIH Clinical Trial website.
Our researchers uncovered MRF-008’s potential to protect and repair myelin, and conducted extensive pre-clinical research. We are now helping to cover trial costs and will be working with NIH investigators to analyze trial data.
We call the drug MRF-008 to denote it as one of the potential therapeutic targets in our pipeline that we are investigating through basic discovery, translational research and clinical development.
Visit the NIH Clinical Trial website.